Why Scholar Rock Holding Corporation (SRRK) stock moved
Scholar Rock Holding Corporation (SRRK) shares tumbled 5.5% to $48.70 as of November 10, 2026, a significant decline from the prior close of $51.55. BestStocks flagged the session as a major change for SRRK. The move is tied to a new SEC filing. Below, we break down what changed for SRRK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
SEC Filing
Scholar Rock stock fell 7.3% on October 5, 2026, driven by profit-taking following the mid-September FDA approval of Isembyld (apitegromab) for spinal muscular atrophy. Investors rotated away from the post-approval rally as focus shifted to commercial execution risks, including launch spending and market uptake timelines. A recent Barclays downgrade to Equal Weight, citing balanced post-approval risk-reward, added to selling pressure amid elevated valuation multiples in the biotech sector.
What it means for Scholar Rock Holding Corporation investors
For Scholar Rock Holding Corporation investors, the recent signals add up to a bearish shift. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction); Positive price momentum. Weighing against that: Sharp 5.5% decline — elevated risk; Scholar Rock Holding Corporation (SRRK) moved -5.07% from $50.88 to $48.30 on July 22, 2026. Wall Street's consensus price target sits at $71.30, implying +46.4% upside from $48.70. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality medium (60/100). With earnings roughly 112 days out, the next report is the most likely near-term test of the move.
SRRK price reaction
SRRK last traded at $48.70, down $2.85 (-5.53%) from the previous close of $51.55. The session traded on 0.2× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $39.60 and $51.55, and it currently sits about 76% of the way up that band.
Bullish and bearish analyst opinions on Scholar Rock Holding Corporation (SRRK)
The consensus analyst price target on Scholar Rock Holding Corporation (SRRK) is $71.30, 46.4% above the recent $48.70. Over the past 90 days analysts logged 0 upgrades, 14 maintains, and 1 downgrade. Here is how the bullish and bearish cases on SRRK line up.
The bullish case
- Wall Street's consensus price target of $71.30 implies +46.4% upside from $48.70.
- The Street's most bullish target is $84.00 (+72.5%).
- Earnings beat — stock sold off (sell-the-news reaction).
- Positive price momentum.
The bearish case
- 1 analyst downgrade in the past 90 days, most recently Barclays to Equal Weight (2026-09-15).
- Sharp 5.5% decline — elevated risk.
- Scholar Rock Holding Corporation (SRRK) moved -5.07% from $50.88 to $48.30 on July 22, 2026.
- SRRK fell 3.09% intraday to $52.26, continuing pressure from a potential delay in an FDA submission announced Monday that triggered a >13% drop.
- SRRK declined 2.91% to $53.40 intraday, with volume running 47% below historical average for this time of session.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for SRRK
In-depth SRRK event analyses
Frequently asked questions about SRRK
Why did Scholar Rock Holding Corporation (SRRK) stock move?
Scholar Rock stock fell 7.3% on October 5, 2026, driven by profit-taking following the mid-September FDA approval of Isembyld (apitegromab) for spinal muscular atrophy. Investors rotated away from the post-approval rally as focus shifted to commercial execution risks, including launch spending and market uptake timelines. A recent Barclays downgrade to Equal Weight, citing balanced post-approval risk-reward, added to selling pressure amid elevated valuation multiples in the biotech sector.
How much did SRRK stock fall?
SRRK lost 5.53% ($2.85) versus the prior close of $51.55, last trading at $48.70 on 0.2× average volume.
When is Scholar Rock Holding Corporation's next earnings date?
SRRK's next earnings report is estimated for 2027-03-02 — about 112 days away.
What is the analyst price target for SRRK?
The consensus analyst price target for SRRK is $71.30, about 46.4% above the current $48.70. Over the past 90 days, analysts recorded 0 upgrades, 14 maintains, and 1 downgrade.
How BestStocks tracks SRRK
This page is generated automatically by BestStocks' change-detection system after a new SEC filing was detected and verified against independent data sources. It draws on 20 tracked change events for SRRK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.